<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03839862</url>
  </required_header>
  <id_info>
    <org_study_id>FAST1</org_study_id>
    <nct_id>NCT03839862</nct_id>
  </id_info>
  <brief_title>Faecal Analyses in Spondyloarthritis Therapy</brief_title>
  <acronym>FAST</acronym>
  <official_title>Faecal Analyses in Spondyloarthritis Therapy: A Prospective Observational Study of the Intestinal Microbiome in Patients With Spondyloarthropathy Receiving TNF-inhibition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the intestinal microbiome and disease activity in patients with&#xD;
      spondyloarthropathies receiving immunosuppressive therapy.&#xD;
&#xD;
      Patients will be analysed at two time points in reference to two predefined primary&#xD;
      endpoints:&#xD;
&#xD;
        -  Changes in intestinal microbiome&#xD;
&#xD;
        -  Response to therapy&#xD;
&#xD;
      The investigators want to evaluate if successful treatment of spondylarthropathy coincide&#xD;
      with specific changes in the gut flora.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumor necrosis factor (TNF)-inhibition is an efficient medication for the treatment of&#xD;
      spondyloarthropathy. In a substantial number of cases however, these medications remain&#xD;
      ineffective. At present, the scientific community has limited understanding of why some&#xD;
      patients are resistant to this medication. The purpose of this study is to understand if the&#xD;
      gut flora may associate with treatment response.&#xD;
&#xD;
      Spondyloarthropathies are associated with inflammatory bowel diseases in terms of&#xD;
      epidemiology and molecular pathogenesis. Recent studies have also associated&#xD;
      spondyloarthropathies with intestinal dysbiosis.&#xD;
&#xD;
      This study is of observational character and integrated in the routine clinical care of&#xD;
      patients with spondyloarthropathies at the Rheumatology Clinic, Skane University Hospital,&#xD;
      Lund, Sweden. Study participants are asked to deliver blood and fecal sampling at two&#xD;
      time-points together with clinical evaluation of disease activity. With an estimated&#xD;
      inclusion of 50 patients, at least 20 responders and 20 non-responders are expected to be&#xD;
      included and to be compared to each other.&#xD;
&#xD;
      Our primary goal is to investigate the association between change in intestinal microbiome&#xD;
      and clinical response to therapy.&#xD;
&#xD;
      In our secondary analyses we will investigate if intestinal microbiome and intestinal&#xD;
      inflammation at baseline may predict response to, and adherence to, therapy in these&#xD;
      patients.&#xD;
&#xD;
      If successful treatment response of spondyloarthropathy is associated with specific&#xD;
      alterations of the gut flora, these results may guide future studies on the impact of&#xD;
      dysbiosis and probiotics on this disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gut flora</measure>
    <time_frame>Change from baseline Dysbiosis Index Score at 6 months</time_frame>
    <description>Change in Dysbiosis Index Score att follow up compared to baseline. The Dysbiosis Index Score measures degree of intestinal dysbiosis on a scale from 1 to 5, where 5 indicates dysbiosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in disease activity/treatment response at follow up</measure>
    <time_frame>Change from baseline BASDAI at 6 months</time_frame>
    <description>Change in Bath Ankylosing Spondylitis Disease Activity Score (BASDAI), an established index of disease activity in spondylarthropathies between 0-10, where 10 equals maximum activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal gut flora in spondyloarthropathies</measure>
    <time_frame>Analysis made at study start /baseline</time_frame>
    <description>Intestinal gut flora based on DNA-based microbial analysis of fecal samples (Dysbiosis Index Score). The Dysbiosis Index Score measures degree of intestinal dysbiosis on a scale from 1 to 5, where 5 indicates dysbiosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal gut inflammation</measure>
    <time_frame>Analysis made at study start /baseline</time_frame>
    <description>Assessment of intestinal inflammation by measurement of faecal calprotectin, an established biomarker of intestinal inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to immunosuppressive therapy</measure>
    <time_frame>Analysis made at 6 months follow up</time_frame>
    <description>Is the patient still prescribed the same immunosuppressant compared to baseline?</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Spondyloarthropathies</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Responder</arm_group_label>
    <description>Patient responding to TNF-inhibition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-Responder</arm_group_label>
    <description>Patient not responding to TNF-inhibition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF-inhibition</intervention_name>
    <description>Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab</description>
    <arm_group_label>Responder</arm_group_label>
    <arm_group_label>non-Responder</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and faecal sampling&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study encompasses consecutive patients with spondyloarthropathy who by their physician&#xD;
        at the Rheumatology Clinic, Skåne University Hospital, have been prescribed a&#xD;
        TNF-inhibitor.&#xD;
&#xD;
        Patients who are willing to comply with the study protocoll are included. The study&#xD;
        population is consequently not a sample, but encompasses a majority of spondyloarthropathy&#xD;
        patients being prescribed this medication at our University clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfilling the Assessment of SpondyloArthritis International Society classification&#xD;
             criteria for spondyloarthropathy.&#xD;
&#xD;
          -  About to commence treatment with TNF-inhibition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to understand protocol&#xD;
&#xD;
          -  A history of alcohol abuse&#xD;
&#xD;
          -  Any history of diverticulitis&#xD;
&#xD;
          -  A history of failure to comply with prescribed medication&#xD;
&#xD;
          -  Ongoing biological therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristofer Andréasson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristofer Andréasson, MD PhD</last_name>
    <phone>+4646172153</phone>
    <email>kristofer.andreasson@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johan Karlsson Wallman, MD PhD</last_name>
    <phone>+4646172140</phone>
    <email>johan.81.karlsson@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reumatologi SUS Lund, Region Skåne</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristofer Andréasson, MD PhD</last_name>
      <phone>+4646171000</phone>
      <email>kristofer.andreasson@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Johan Karlsson Wallman, MD PhD</last_name>
      <phone>+4646171000</phone>
      <email>johan.81.karlsson@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Spondylarthropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

